Year All2024202320222021 KemPharm Issues Letter to Shareholders 06-16-2021 KemPharm to be Added to Russell 2000® and Russell 3000® Indexes Effective June 28, 2021 06-09-2021 KemPharm Executives to Participate in Panel Discussions During Upcoming June 2021 Conferences 06-03-2021 KemPharm, Inc. Announces Orange Book Listing for Six Patents Covering Serdexmethylphenidate (SDX) and Confirmation of NCE Status 05-26-2021 KemPharm Reports First Quarter 2021 Financial Results 05-13-2021 KemPharm Announces Serdexmethylphenidate (SDX) Has Been Classified as a Schedule IV Controlled Substance by the DEA 05-07-2021 KemPharm to Report First Quarter 2021 Results 05-06-2021 KemPharm Confirms Receipt of $10 Million Milestone Payment for FDA Approval of AZSTARYS™ Per License Agreement with Affiliate of Gurnet Point Capital 04-21-2021 KemPharm Announces Amendment to Licensing Agreement with Gurnet Point Capital Affiliate Following FDA Approval of AZSTARYS™ 04-08-2021 KemPharm Reports Fourth Quarter and Full-Year 2020 Financial Results 03-11-2021
KemPharm Executives to Participate in Panel Discussions During Upcoming June 2021 Conferences 06-03-2021
KemPharm, Inc. Announces Orange Book Listing for Six Patents Covering Serdexmethylphenidate (SDX) and Confirmation of NCE Status 05-26-2021
KemPharm Announces Serdexmethylphenidate (SDX) Has Been Classified as a Schedule IV Controlled Substance by the DEA 05-07-2021
KemPharm Confirms Receipt of $10 Million Milestone Payment for FDA Approval of AZSTARYS™ Per License Agreement with Affiliate of Gurnet Point Capital 04-21-2021
KemPharm Announces Amendment to Licensing Agreement with Gurnet Point Capital Affiliate Following FDA Approval of AZSTARYS™ 04-08-2021
